打开APP

Cardinal Health将以19.4亿美元收购强生心脏医疗设备业务

  1. Cardinal Health
  2. 医疗设备
  3. 强生
  4. 收购

来源:生物谷 2015-03-04 12:58

Cardinal Health Inc周一宣布将以19.4亿美元收购强生的心脏业务单元。

Cardinal Health将以19.4亿美元收购强生心脏医疗设备业务

2015年3月4日讯/生物谷BIOON/--Cardinal Health Inc.是俄亥俄州一家专门从事药品和医疗器械销售的公司,周一宣布将以19.4亿美元收购强生的心脏业务单元,以丰富其心血管设备的种类,扩大目前产品的投资组合。

Cardinal Health当下抓住了并购的好时机,收购了包括支架、导管等手术中需要的心血管医疗器械。此番Cordis势必会加强其在心血管器械市场上的竞争力,与Abbott Laboratories、Boston Scientific Corporation和 Medtronic PLC等心血管设备制造商一决高下。

如果此次收购成功,将会极大地促进Cardinal Health的销售额,并且赋予Cardinal Health与保险公司和医院更强的议价能力,此前保险公司与医院通过与许多家公司谈判来获得更大额度的折扣。Cardinal Health的医疗部负责人Don Casey表示,Cardinal Health对医院的重要性与日俱增。

2014年,强生的心脏业务单元共为公司带来了7.8亿美元的销售额,其中心脏和血管产品的收益是平分秋色。其中约70%的销售额来源于国际市场,包括中国、日本、巴西、德国、意大利、法国和英国等50多个国家。Cardinal Health在2014年销售额为910亿美元,收购之后将会具备更强劲的增长势头。

Cardinal Health的董事长、首席执行官George Barrett就收购强生的心脏业务单元表示,此番收购对增强公司在心血管设备方面是非常关键的一步,强生在心血管设备的创新能力非常强劲。

Cardinal Health预计收购完成后将会促使公司到2017年的股价每股增加0.2美元,到2018年底,每年能带来超过一亿美元的协同增效。

此次收购对强生也有好处,强生一直在寻求机会缩减其庞大的投资组合,集中尽力在关键的产品上。出售心脏业务单元后,强生每年能减少10亿美元的成本。强生的CEO Alex Gorsky表示,强生已经开始剥离小业务。

据悉此次并购将于今年年底结束,主要以现金和10亿美元信贷的形式支付,其中主要包括无担保优先债券。(生物谷Bioon.com)

详细英文报道 Cardinal Health Inc (CAH) To Acquire Johnson & Johnson Cordis Unit In A $1.94 Billion Deal

Cardinal Health Inc. (NYSE:CAH), an Ohio-based company specializing in the distribution of pharmaceuticals and medical equipment, announced Monday its plans to acquire Johnson & Johnson’s (NYSE:JNJ) Cordis business unit for $1.94 billion, in a move to expand its current portfolio of products to include various cardiovascular devices.

Cardinal Health has made a smart move by grabbing a timely opportunity to acquire the global manufacturer of cardiology and endovascular devices, including stents, catheters, and guide wires used in various surgical procedures. The Cordis acquisition is poised to strengthen the company’s position in the cardiovascular devices market, against major rival cardiovascular device-makers including Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC.

The deal would boost sales for Cardinal Health, while giving the company greater bargaining power against insurers and hospitals who have begun to successfully negotiate higher discounts by playing off companies against one another.

“As we bring more of these strategies to bear, that’s going to make us increasingly important to hospitals,” said Don Casey, head of Cardinal Health’s medical segment, as reported in the company’s press release yesterday.

California-based Cordis, which generated sales of $780 million for the full year 2014, has its revenue divided equally between cardiology and endovascular products. The unit garners approximately 70% of its sales internationally, from more than 50 countries including China, Japan, Brazil, Germany, Italy, France, and the UK. Cardinal Health, who reported sales of $91 billion for the full fiscal 2014, is well-equipped to further enhance the growth momentum for Cordis.

George Barrett, chairman and chief executive officer at Cardinal Health, commented on the company’s decision to acquire Cordis in a press release yesterday: "We are extremely excited about the acquisition of Cordis. This is a significant step forward in our cardiovascular strategy. Cordis brings with it a long and proud legacy of cardiovascular innovation.

Cardinal Health expects the deal to result in additional adjusted earnings of $0.2 per share in 2017, while resulting in significant synergies of more than $100 million for each year from the end of fiscal year 2018.

The deal would also offer significant advantages to J&J as well, which is looking to shrink its large portfolio to focus more on developing its top-selling businesses. The Cordis sale is in line with the company’s plan to achieve the cost-reduction target of $1 billion for each year.

“The company is open to divesting smaller business,” commented J&J CEO Alex Gorsky.

The Cordis acquisition, expected to be completed by the end of this year, will be financed by Cardinal Health through cash as well as $1 billion of new credit sources, including new senior unsecured notes mainly.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->